Land: Australien
Sprog: engelsk
Kilde: Department of Health (Therapeutic Goods Administration)
tenofovir disoproxil fumarate, Quantity: 300 mg
Hetero Australia Pty Ltd
Tablet
Excipient Ingredients: microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin
Oral
30's
(S4) Prescription Only Medicine
TENOFOVIR HETERO in combination with other antiretroviral agents is indicated for the treatment of HIV-infected adults and paediatric patients 12 years of age and older.,TENOFOVIR HETERO is indicated for the treatment of chronic hepatitis B in adults (see CLINICAL TRIALS)..,TENOFOVIR HETERO is indicated for the treatment of chronic hepatitis B in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e, active viral replication, persistently elevated serum ALT levels or evidence of active inflammation.
Visual Identification: White coloured, almond shaped, film-coated tablets debossed with 'H' on one side and '123' on the other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2018-12-06